Lundbeck profit jumps but warns on generic pressure

Danish pharmaceutical company Lundbeck Wednesday posted a higher than expected quarterly net profit, helped by the expansion of an alliance with Japan's Otsuka and the divestment of a US portfolio of non-core products.

Net profit in the first quarter rose 72 percent to DKK1.07 billion (144 million euros, $189 million) as revenue grew 21 percent to DKK4.58.

Analysts polled by Newswires had expected an average net profit of DKK662.1 million and revenue to come in at DKK4.01 billion.

Chief executive Ulf Wiinberg said he was pleased with the results, but added there was also "reason to be cautious" as Alzheimer's treatment Ebixa would face increased competition from , and launch costs were expected to rise.

"Therefore, we are maintaining the guidance for the year," he said.

The Copenhagen-based company, which has lost in several markets on blockbuster antidepressant Lexapro, said it's "investing significantly in several new product launches and increased pipeline activity."

Lundbeck expects full-year revenue to be between DKK14.4 billion and DKK15.0 billion, and profit from operations (EBIT) to be in the range of DKK1.9 billion to 2.4 billion.

The deal with Otsuka resulted in a DKK284 upfront payment in the period, while Lundbeck gained DKK454 million from the divestment of its US portfolio of non-core products.

add to favorites email to friend print save as pdf

Related Stories

Danish Novo Nordisk profit surges

Jan 31, 2013

Danish pharmaceutical company Novo Nordisk A/S on Thursday reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide begin to approve its ...

Taiwan's HTC expects 30 percent sales plunge in 1Q

Feb 06, 2012

Taiwan's leading smartphone maker HTC forecast Monday that its revenue in the three months to March may plunge 30 percent from a year ago, as competitors Apple and Samsung take their grip on the market.

Diabetes drugs helps boost Novo Nordisk in Q2

Aug 09, 2012

(AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.

Recommended for you

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments